Impact of genetic variants of \textit{ABCB1}, \textit{APOB}, \textit{CAV1}, and \textit{NAMPT} on susceptibility to pancreatic ductal adenocarcinoma in Chinese patients

Baohuan Li\textsuperscript{1} | Chuanzhen Zhang\textsuperscript{2} | Jingjing Wang\textsuperscript{3} | Meijuan Zhang\textsuperscript{2} | Changhong Liu\textsuperscript{2} | Ziping Chen\textsuperscript{2}

\textsuperscript{1}Department of Gastroenterology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China
\textsuperscript{2}Department of Gastroenterology, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, China
\textsuperscript{3}Clinical Laboratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, China

Correspondence
Chuanzhen Zhang, Department of Gastroenterology, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, China. Email: fax8446@126.com

Funding information
Shandong province key research and development plan project, Grant/Award Number: 2017GG06025; Shandong province medical and health's science and technology development plan project, Grant/Award Number: 2016WS0477

Abstract
\textbf{Background:} Among the different types of cancer, pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), is the most lethal malignancy, with poor early detection rates and prognosis. The aim of the present study was to investigate the potential genetic effects of the single-nucleotide polymorphisms (SNPs) in \textit{ABCB1} (rs1045642, rs3789243, rs4148737), \textit{APOB} (rs693, rs1042031), \textit{CAV1} (rs12672038, rs1997623, rs3807987, rs7804372), and \textit{NAMPT} (rs9034, rs2505568, rs61330082) on PDAC.

\textbf{Methods:} A total of 273 patients with PDAC and 263 healthy controls were genotyped using PCR and direct Sanger sequencing. Unconditional logistic regression models were used to evaluate the potential effects of the genotypes, alleles, and haplotypes on the risk of developing PDAC.

\textbf{Results:} Patients with PDAC possessed a considerably lower frequency of genotypes AG, GG, and allele G at \textit{ABCB1} rs4148737 compared with controls. Based on age, sex, smoking status, drinking status, diabetes, and family history of cancer, stratified analyses showed a significant correlation between SNPs at rs4148737 and PDAC. According to specific SNPs, eight haplotypes were constructed along with \textit{ABCB1} rs4148737, rs1045642, and rs3789243. Carriers with haplotypes ACC and ATC were more susceptible to developing PDAC, whereas haplotypes GCC and GTC were associated with a reduced likelihood of developing PDAC. The distributions of the other SNPs in each group were not significantly associated with PDAC risk.

\textbf{Conclusions:} These results suggested that genetic polymorphisms of \textit{ABCB1} rs4148737 may influence an individual's risk of developing PDAC.

\textbf{KEYWORDS}
\textit{ABCB1}, \textit{APOB}, \textit{CAV1}, genetic polymorphism, \textit{NAMPT}, pancreatic ductal adenocarcinoma
1 INTRODUCTION

Pancreatic cancer is one of the hardest to treat malignancies. According to GLOBOCAN 2018 estimates, pancreatic cancer is the 11th most common type of cancer worldwide, with 458,918 new cases (accounting for 2.5% of all cases of cancer) and 342,242 deaths (4.5% of all deaths caused by cancer) (Bray et al., 2018). Additionally, the number of cancer death ranked the seventh in developed countries (Bray et al., 2018), and its number of cancer death ranked third in the USA (Siegel, Miller, & Jemal, 2019). In China, it was the 10th most common malignant carcinoma in 2015 (2.42% of all cancer cases), and it is the sixth leading cause of cancer-associated death (3.64% of all cancer-associated deaths) (Zheng et al., 2019).

The etiology of pancreatic cancer has been extensively studied by numerous meta-analyses and pooled analyses. Thus far, several risk factors can be divided into two primary categories: Modifiable and non-modifiable. The former includes smoking, alcohol, dietary factors, obesity, and exposure to toxic substances, whereas the latter includes ethnicity, sex, age, family history of pancreatic cancer, diabetes mellitus, genetic factors, chronic infections, non-O blood group, and chronic pancreatitis (Midha, Chawla, & Garg, 2016). However, the specific etiology has been not defined. Although several pathological types of pancreatic malignancies have been identified, pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor are the most prevalent, which account for 90% and 5%, respectively (Hackeng, Hruban, Offerhaus, & Broens, 2016). Additionally, patients with an early stage of pancreatic cancer do not typically exhibit symptoms. However, as the cancer progresses, it may physically manifest as a gradual onset of nonspecific symptoms, such as jaundice, light-colored stools, abdominal pain, weight loss, and fatigue (Siegel, Miller, & Jemal, 2018). The available diagnostic tests for detection include measuring the blood levels of cancer antigen 19–9, abdominal ultrasonography, tri-phasic pancreatic protocol CT, magnetic resonance imaging, and endoscopic ultrasound-guided fine-needle aspiration for cytological diagnosis (the sensitivity of which is reported to be ~80%) (Longnecker, Karagas, Tosteson, & Mott, 2000). Nonetheless, they are nonspecific and may miss numerous patients with early stage pancreatic cancer (De La Cruz, Young, & Ruffin, 2014). Therefore, pancreatic cancer is usually diagnosed at the advanced stage, and 80%–90% of patients present with unresectable tumors at the first diagnosis (Rawla, Sunkara, & Gaduputi, 2019). Once a definite diagnosis has been made, surgery, chemotherapy, and radiotherapy are traditionally used to extend the patients’ survival and/or relieve their symptoms. However, for patients with advanced-stage pancreatic cancer, there is still no definitive or effective cure (Mohammed, Van Buren, & Fisher, 2014).

Prevention, early detection, and curing the disease in the early stages are key to reduce the morbidity and mortality rates. Novel etiological agent or more specific diagnostic tools may result in improved outcomes for patients. Thus, there is a need for ongoing evaluation for the epidemiology of this malignancy. Among the factors which need to be assessed, genetic variations or mutations serve an important role in the increased risk of pancreatic cancer (Ghiorzo, 2014). Of the patients with pancreatic cancer, ~10% possess a genetic predisposition to developing the malignancy (Shi, Daniels, & Hruban, 2008). Several germline mutations have been demonstrated to be involved in hereditary forms of pancreatic cancer, such as BRCA1 (OMIM # 117,705), BRCA2 (OMIM # 600,185), PALB2 (OMIM # 610,355), ATM (OMIM # 607,585), APC (OMIM # 611,731), MLH1 (OMIM #120436), MSH2 (OMIM # 609,309), MSH6 (OMIM # 600,678), PMS2 (OMIM # 600,259), BRIP1 (OMIM # 276,000), and STK11 (OMIM # 602,216) (Solomon, Das, Brand, & Whitcomb, 2012; Vincent, Herman, Schulick, Hruban, & Goggins, 2011).

The ATP-binding cassette subfamily B member 1 (ABCB1 [OMIM #171050]), also known as multidrug resistance gene 1, encodes a transmembrane P-glycoprotein (P-gp). This protein functions to efflux of endogenous metabolites and toxic xenobiotics, including intracellular carcinogens, suggesting its protective role against carcinogenesis. P-gp also serves an important role in the reduction of drug response, through modulating absorption, metabolism, and promoting elimination of drugs from cells. P-gp also activates lymphocytes during the immune response (Hodges et al., 2011). It is speculated that genetic polymorphisms of ABCB1 may result in variations in the expression levels of the mRNA transcript and protein, or result in misfolded proteins, and reduced or altered substrate specificity, which will likely influence drug pharmacokinetics or disease outcome (Fung & Gottesman, 2009). Several studies have reported the association between ABCB1 polymorphisms with cancer risk, and the results were not consistent absolutely (He, Mo, Zhang, & Liu, 2013; Ruiz-Pinto et al., 2016; Sabahi et al., 2010; Sam et al., 2007; Yan et al., 2019).

Obesity is associated with an increased risk of pancreatic cancer (Davoodi, Malek-Shahabi, Malekshah-Moghadam, Shahbazi, & Esmaeili, 2013) and it may increase the incidence and mortality of pancreatic cancer (Berrington de Gonzalez, Sweetland, & Spencer, 2003; Calle, Rodriguez, Walker-Thurmond, & Thun, 2003). Abnormal lipid metabolism promotes pancreatic tumorigenesis (Guillaumond et al., 2015; Ying et al., 2016). The apolipoprotein B (APOB) protein forms an integral part of chylomicrons and very low-density lipoproteins during lipoprotein metabolism. Several SNPs in APOB (OMIM # 107,730) have been reported, although their significance to cancer has not been
studied, to the best of our knowledge. Therefore, whether they influence the progression of pancreatic carcinoma remains to be determined.

Caveolin 1 (CAV1) serves an important role in cell signaling regulation and acts as a scaffold involved in various signaling ways. For example, the caveolin-scaffolding domain negatively regulates the activity of numerous signaling molecules, including endothelial nitric oxide synthase (Ju, Zou, Venema, & Venema, 1997) and epidermal growth factor receptor (Couet, Sargiacomo, & Lisanti, 1997). CAV1 (OMIM # 601,047) is expressed in a variety of tumor cells and exhibits carcinogenic and tumor suppressive functions dependent on the specific type of cancer and stage (Gupta, Toufaily, & Venema, 1997). CAV-1 and epidermal growth factor receptor (Couet, Sargiacomo, & Lisanti, 1997) and epidermal growth factor receptors (Couet, Sargiacomo, & Lisanti, 1997). CAV1 expression may inhibit tumor growth in the early stages of cancer, and promote its invasion and metastasis in the later stages (Shatz & Liscovitch, 2008). To date, numerous studies have explored the association between genetic polymorphisms of CAV1 and hepatocellular, colorectal, and gastric cancers (Hsu et al., 2013; Yang et al., 2010; Zhang, Hu, et al., 2014).

Nicotinamide phosphoribosyltransferase (NAMPT) was initially identified as a pre-B-cell colony-enhancing factor. NAMPT is also a rate-limiting enzyme in NAD biosynthesis, which is crucial for numerous vital cellular processes, genomic stability, and organismal metabolic homeostasis (Shackelford, Mayhall, Maxwell, Kandil, & Coppola, 2013; Ying, 2008). Additionally, NAMPT is involved in angiogenesis by activating the extracellular signal-regulated kinase 1/2 pathway, and increasing the expression of vascular endothelial growth factor and matrix metalloproteinase 2/9 (Kim et al., 2007). NAMPT (OMIM # 608,764) is highly evolutionarily conserved, suggesting that even small genetic variations may profoundly affect its protein expression, function, and subsequent dependent events.

Based on the above, certain SNPs of these proteins, which may affect protein expression, structure, or function, may be associated with genetic susceptibility to PDAC. However, to the best of our knowledge, there are no studies which have investigated the potential association between these SNPs and the risk of PDAC. Thus, the aim of the present study was to analyze the relationships between SNPs of ABCB1 (rs1045642 [HGVS Name: g.208920T>C], rs3789243 [HGVS Name: g.126679T>C], rs4148737 [HGVS Name: g.176413A>G]), APOB (rs693 [HGVS Name: g.39751C>T], rs1042031 [HGVS Name: g.46193G>A]), CAV-1 (rs12672038 [HGVS Name: g.27268G>A], rs1997623 [HGVS Name: g.5522A>C], rs3807987 [HGVS Name: g.19996G>A], rs7804372 [HGVS Name: g.34390T>A]), and NAMPT (rs9034 [HGVS Name: c.1437T>C], rs2505568 [HGVS Name: g.1929A>T], rs61330082 [HGVS Name: g.106286419G>A]), and the hereditary susceptibility of PDAC in Chinese patients.

### 2 MATERIALS AND METHODS

#### 2.1 Study participants

Between January 2015 and December 2018, 273 patients with PDAC (165 males and 108 females) who visited Shandong Provincial Qianfoshan Hospital were recruited. All diagnoses were confirmed by qualified pathological analysis of surgical specimens or endoscopic ultrasound-guided fine-needle aspiration. Every slide was confirmed by two pathologists in Shandong Provincial Qianfoshan Hospital independently, while the disagreement was resolved by the senior pathologists. None of the patients recruited received chemotherapy or any other treatments for PDAC prior to recruitment. Moreover, patients with incomplete clinical information and histories of previous cancers or autoimmune diseases were excluded in this study.

The control group composed of 269 healthy and genetically unrelated individuals (130 males and 139 females), with age between 25 and 80 years, randomly selected from Shandong permanent residents over the same period. They were voluntary participants without any known history of cancer, psychological disorders, autoimmune diseases of the pancreas, cardiocerebral vascular diseases, or infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

Each participant provided written informed consent for participation in the study, and their demographic and lifestyle characteristics were collected and recorded by one-on-one interviews. A history of regular cigarette smoking was defined as ≥1 cigarette per day for ≥12 months, or ≥18 packs for 1 year, while individuals drinking Chinese liquor ≥50 ml, or beer ≥200 ml biweekly for 12 months were thought as positive history of drinking.

#### 2.2 DNA extraction

A total of 3 ml of peripheral blood was drawn from each patient, and the genomic DNA was extracted using a Blood DNA kit according to the manufacturer's protocol (Omega Bio-Tek, Inc.).

#### 2.3 Genotyping

Genomic DNA was amplified using PCR. The sequencing primers used were the same as previous studies (Al-Bustan, Alnaqeeb, Annice, Ebrahim, & Refai, 2014; Caronia et al., 2011; He et al., 2013; Wang, Zhang, Liu, Xu, & Chen, 2014; Zhang et al., 2015). PCR amplification was performed in a total of 25-μl reaction mixture, containing 100–150 ng genomic DNA, 0.5 μl of each primer (10 μM each; Shanghai Boshang Biotechnology Co., Ltd.), 0.5-μl dNTP (10 mM), and 1.5 U Taq
DNA polymerase (Takara Bio, Inc.). The thermocycling conditions were: Initial denaturation for 2 min at 94°C; followed by 38 cycles of 30 s at 94.0°C, 50 s at the respective annealing temperatures and 1 min at 72.0°C; and a final extension step of 5 min at 72.0°C. All PCR products were run on 2% agarose gels and imaged. Genotypes were identified using direct Sanger sequencing (Shanghai Boshang Biotechnology Co., Ltd.).

2.4 Statistical analysis

Comparison of age distribution between the two groups was performed using a Mann–Whitney U test. Differences in the other demographic variables were compared using a McNemar test. To verify that all subjects were selected from a representative population, a χ² goodness-of-fit test was used to test genotypes for Hardy–Weinberg equilibrium. PHASE software (version 2.1, University of Chicago) haplotype and haplotype frequencies were constructed and estimated. The odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using unconditional logistic regression models. The adjusted ORs and 95% CIs were derived from logistic models adjusted for age, sex, smoking, alcohol consumption, diabetes, and family history of cancer. All statistical analyses were two-sided and performed in Stata 15.1 (StataCorp LP). p < .05 was considered to indicate a statistically significant difference.

3 RESULTS

3.1 Distribution of patient characteristics

Table 1 shows the distribution of characteristics in the patients with PDAC and the healthy controls. The mean age (mean ± SD) of cases and controls were 64.56 ± 12.11 years and 63.31 ± 9.40 years, respectively, and there was no significant difference (p = .060). Alcohol consumption and incidence of diabetes were also not significantly different between the two groups (p = .086 and p = .093, respectively). There was a significant difference in the distribution of sex, tobacco consumption, and family history of cancer between the two groups (p = .005, p < .001, and p = .009, respectively). Specially, the frequencies of males, smokers, or individuals with family history of cancer were much higher in cases than controls (60.44% versus 48.33%; 30.77% versus 17.73%; 21.25% versus 12.64%, respectively).

3.2 Association between genetic polymorphisms and PDAC susceptibility

All genotype and allele frequencies of the SNPs examined are presented in Table 2. The distribution of these genotypes in each group did not deviate from the Hardy–Weinberg equilibrium (p > .05). After adjustment for confounding factors (age, sex, smoking, drinking, diabetes, and family history of cancer) in an unconditional logistic regression model, patients with PDAC possessed significantly lower frequencies of genotypes AG, GG, and allele G at rs4148737 compared with the controls (26.79% versus 45.73%, p < .001; 7.17% versus 21.79%, p < .001; 20.57% versus 44.66%, p < .001, respectively). Furthermore, subjects with genotypes AG, GG, and allele G were less susceptible to developing PDAC (OR = 0.29, 95% CI: 0.19–0.43; OR = 0.16, 95% CI: 0.09–0.30; OR = 0.32, 95% CI: 0.24–0.43, respectively). No significant differences were observed between the frequencies of any other SNPs between patients with PDAC and the control group (p > .05).

3.3 Stratification analyses of ABCB1 genetic polymorphisms and PDAC susceptibility

To evaluate the effect of genetic polymorphism at rs4148737 on the susceptibility of PDAC, subjects were stratified based on age, sex, smoking status, drinking status, presence of diabetes,
| Genotype | Cases (n = 273) | Controls (n = 269) | Crude OR (95% CI) | p | Adjusted ORa (95% CI) | p^a |
|----------|----------------|-------------------|-------------------|---|----------------------|----|
| rs1045642 |                |                   |                   |   |                      |    |
| CC       | 82 30.71       | 72 30.25          | 1.00              |   | 1.00                 |    |
| CT       | 118 44.19      | 127 53.36         | 0.82 (0.54–1.22)  | .323 | 0.76 (0.50–1.15) | .190 |
| TT       | 67 25.09       | 39 16.39          | 1.51 (0.91–2.50)  | .111 | 1.50 (0.89–2.51) | .126 |
| C Allele | 282 52.81      | 271 56.93         | 1.00              |   | 1.00                 |    |
| T Allele | 252 47.19      | 205 43.07         | 1.18 (0.92–1.51)  | .189 | 1.16 (0.90–1.49) | .256 |
| rs3789243 |                |                   |                   |   |                      |    |
| CC       | 115 43.4       | 111 45.49         | 1.00              |   | 1.00                 |    |
| CT       | 119 44.91      | 110 45.08         | 1.04 (0.72–1.51)  | .818 | 1.04 (0.72–1.52) | .829 |
| TT       | 31 11.7        | 23 9.43           | 1.30 (0.71–2.37)  | .389 | 1.37 (0.74–2.52) | .315 |
| C Allele | 349 59.45      | 332 60.14         | 1.00              |   | 1.00                 |    |
| T Allele | 238 40.55      | 220 39.86         | 1.10 (0.85–1.43)  | .46  | 1.13 (0.87–1.48) | .355 |
| rs4148737 |                |                   |                   |   |                      |    |
| AA       | 175 66.04      | 76 32.48          | 1.00              |   | 1.00                 |    |
| AG       | 71 26.79       | 107 45.73         | 0.29 (0.19–0.43)  | <.001 | 0.29 (0.19–0.43) | <.001 |
| GG       | 19 7.17        | 51 21.79          | 0.16 (0.09–0.29)  | <.001 | 0.16 (0.09–0.30) | <.001 |
| A Allele | 421 79.43      | 259 55.34         | 1.00              |   | 1.00                 |    |
| G Allele | 109 20.57      | 209 44.66         | 0.32 (0.24–0.42)  | <.001 | 0.32 (0.24–0.43) | <.001 |
| rs693     |                |                   |                   |   |                      |    |
| CC       | 234 89.31      | 199 87.28         | 1.00              |   | 1.00                 |    |
| TC       | 26 9.92        | 19 8.33           | 1.16 (0.63–2.17)  | .632 | 1.15 (0.61–2.17) | .671 |
| TT       | 2 0.76         | 10 4.39           | 0.17 (0.04–0.79)  | .023 | 0.18 (0.04–0.85) | .030 |
| C Allele | 494 94.27      | 417 91.45         | 1.00              |   | 1.00                 |    |
| T Allele | 30 5.73        | 39 8.55           | 0.65 (0.40–1.06)  | .086 | 0.64 (0.39–1.06) | .083 |
| rs1042031 |                |                   |                   |   |                      |    |
| GG       | 231 86.52      | 211 86.83         | 1.00              |   | 1.00                 |    |
| AG       | 36 13.48       | 30 12.35          | 1.10 (0.65–1.84)  | .729 | 1.04 (0.61–1.76) | .897 |
| AA       | 0 0            | 2 0.82            | —                 |   | —                    |    |
| G Allele | 498 93.26      | 452 93            | 1.00              |   | 1.00                 |    |
| A Allele | 36 6.74        | 34 7              | 0.96 (0.59–1.56)  | .873 | 0.92 (0.56–1.50) | .728 |
| rs12672038 |               |                   |                   |   |                      |    |
| GG       | 146 54.68      | 134 55.37         | 1.00              |   | 1.00                 |    |
| AG       | 106 39.7       | 92 38.02          | 1.06 (0.73–1.52)  | .764 | 1.05 (0.72–1.52) | .811 |
| AA       | 15 5.62        | 16 6.61           | 0.86 (0.41–1.81)  | .692 | 0.90 (0.43–1.92) | .793 |
| G Allele | 398 74.53      | 360 74.38         | 1.00              |   | 1.00                 |    |
| A Allele | 136 25.47      | 124 25.62         | 0.99 (0.75–1.32)  | .956 | 0.99 (0.75–1.32) | .969 |
| rs1997623 |                |                   |                   |   |                      |    |
| CC       | 248 92.88      | 219 89.39         | 1.00              |   | 1.00                 |    |
| AC       | 17 6.37        | 24 9.8            | 0.63 (0.33–1.20)  | .155 | 0.66 (0.34–1.27) | .209 |
| AA       | 2 0.75         | 2 0.82            | 0.88 (0.12–6.32)  | .901 | 1.11 (0.15–8.07) | .919 |
| C Allele | 513 96.07      | 462 94.29         | 1.00              |   | 1.00                 |    |
| A Allele | 21 3.93        | 28 5.71           | 0.68 (0.38–1.21)  | .185 | 0.72 (0.40–1.29) | .969 |

(Continues)
and family history of cancer (Table 3). Compared with genotype AA, significantly decreased frequencies of genotypes AG and GG were detected among male patients with PDAC (adjusted OR = 0.22, 95% CI: 0.13–0.37), female cases (adjusted OR = 0.27, 95% CI: 0.15–0.47), patients in different age brackets (<60-year-old, adjusted OR = 0.18, 95% CI: 0.09–0.36; 60- to 80-year-old, adjusted OR = 0.30, 95% CI: 0.19–0.49; >80-year-old, adjusted OR = 0.09, 95% CI: 0.01–0.69, respectively), patients who had previously smoked or did smoke (adjusted OR = 0.22, 95% CI: 0.10–0.51), patients who never smoked (adjusted OR = 0.25, 95% CI: 0.16–0.39), patients who consumed alcohol (adjusted OR = 0.21, 95% CI: 0.08–0.56), patients who did consume alcohol (adjusted OR = 0.25, 95% CI: 0.17–0.38), patients with diabetes (adjusted OR = 0.36, 95% CI: 0.13–0.99), patients without diabetes (adjusted OR = 0.24, 95% CI: 0.16–0.36), patients with a family history of cancer (adjusted OR = 0.11, 95% CI: 0.04–0.33), and without a family history (adjusted OR = 0.28, 95% CI: 0.19–0.42).

### 3.4 Association between ABCB1 haplotypes and PDAC susceptibility

After identifying the genotypes of the three SNPs of ABCB1, eight haplotypes were constructed using PHASE version 2.1 software. Table 4 shows the distribution of
the estimated haplotypes in each group. It implied that haplotypes ACC (rs4148737A-rs1045642C-rs3789243C) and ATC (rs4148737A-rs1045642T-rs3789243C) were present more frequently in patients with PDAC compared with the control group (11.93% versus 12.87%; 0.64% versus 12.68%, respectively). Using unconditional logistic regression models adjusted for the confounding factors, the association between haplotypes and PDAC risk was calculated and is shown in Table 5. Carriers with haplotype ACC (a/- + a/a) or ATC (c/- + c/c) were observed to have increased susceptibility to PDAC (OR = 1.58, 95% CI: 1.02–2.45; OR = 2.16, 95% CI: 1.47–3.18, respectively), but patients with haplotype GCC (e/- + e/e) or GTC (g/- + g/g) had reduced susceptibility (OR = 0.46, 95% CI: 0.30–0.71; OR = 0.04, 95% CI: 0.01–0.14, respectively). None of the other haplotypes presented any significant differences (p > .05).

### DISCUSSION

Between 2014 and 2018, the 5-year survival rate of pancreatic cancer increased from 6% to 9% (Bray et al., 2018), suggesting that although progress is being made, there is still a need to improve the treatments and outcomes. Pancreatic cancer remains one of the most lethal malignancies, with poor prognoses and a mortality/incidence ratio of 94% (Bray et al., 2018). Due to its atypical clinical features, nonspecific, diagnostic tools which lack specificity and no definitive cures for patients with advanced-stage pancreatic cancer, the 1-year survival rate of pancreatic cancer has been significantly reduced from 25% to <5% (Sarnecka, Zagozda, & Durlik, 2016). Despite advances in our understanding of this disease and potential risk factors, and advances in diagnostic tools to improve early detection, the incidence is estimated to increase with a predicted 355,317 new cases globally in 2040 (Rawla et al., 2019). Thus, it is necessary to improve our understanding of the pathogenesis of PDAC to improve the preventative, diagnostic, and therapeutic approaches. In particular, discovering new tumor biomarkers is of great significance as these biomarkers are valuable tools for improving the accuracy of diagnosis, prevention, and therapy. Among the pathogenic factors underlying the development of cancer, SNPs have been demonstrated to be associated with altered function of methylation enzymes, folate metabolism, inflammation, cell cycle, DNA repair, and also oncogenes, which are suspected to serve a role in the carcinogenesis of PDAC.

### TABLE 3

| Variable                  | rs4148737 (case/control) | p* | Adjusted OR* (95% CI) |
|--------------------------|--------------------------|----|----------------------|
| Gender                   | AA AG + GG               |    |                      |
| Male                     | 108/37 53/80             | 1.00 | <0.001\(0.22 (0.13–0.37)\) |
| Female                   | 67/39 37/78              | 1.00 | <0.001\(0.27 (0.15–0.47)\) |
| Age                      | AA AG + GG               |    |                      |
| <60                      | 62/25 26/54              | 1.00 | <0.001\(0.18 (0.09–0.36)\) |
| 60–80                    | 96/49 59/98              | 1.00 | <0.001\(0.30 (0.19–0.49)\) |
| >80                      | 17/2 5/6                | 1.00 | 0.021\(0.09 (0.01–0.69)\) |
| Smoking                  | AA AG + GG               |    |                      |
| Ever                     | 56/15 25/27              | 1.00 | <0.001\(0.22 (0.10–0.51)\) |
| Never                    | 119/61 65/131            | 1.00 | <0.001\(0.25 (0.16–0.39)\) |
| Drinking                 | AA AG + GG               |    |                      |
| Ever                     | 36/13 12/19              | 1.00 | 0.002\(0.21 (0.08–0.56)\) |
| Never                    | 139/63 78/139            | 1.00 | <0.001\(0.25 (0.17–0.38)\) |
| Diabetes                 | AA AG + GG               |    |                      |
| Yes                      | 31/11 18/20              | 1.00 | 0.049\(0.36 (0.13–0.99)\) |
| No                       | 144/65 72/138            | 1.00 | <0.001\(0.24 (0.16–0.36)\) |
| Family history of cancer | AA AG + GG               |    |                      |
| Yes                      | 38/9 17/25              | 1.00 | <0.001\(0.11 (0.04–0.33)\) |
| No                       | 127/67 73/133            | 1.00 | <0.001\(0.28 (0.19–0.42)\) |

*Adjusted for gender, age, tobacco smoking, alcohol consumption, diabetes, and family history of cancer (besides stratified factors accordingly) in unconditional logistic regression.
and Hic1 regulatory motifs (Ruiz-Pinto et al., 2016). Cells with the wild-type SNPs of $ABCB1$ showed drug resistance in a pancreatic cancer cell line (Kasuya et al., 2012), and polymorphic variants of $ABCB1$ were observed to predict improved therapeutic efficacy and survival for patients with potentially resectable pancreatic cancer (Tanaka, Okazaki, Suzuki, Abbruzzese, & Li, 2011). However, there are no studies on the effect of its genetic polymorphism on

| Haplotypes | SNP positions | Cases $(n = 228)$ | Controls $(n = 217)$ |
|-----------|---------------|------------------|-------------------|
|           | rs4148737     | rs1045642        | rs3789243         |                       |
| 1 A C C   | 82 18.11     | 56 12.87         |                   |
| 2 A C T   | 77 16.9      | 60 13.92         |                   |
| 3 A T C   | 155 33.94    | 96 22.09         |                   |
| 4 A T T   | 44 9.55      | 32 7.35          |                   |
| 5 G C C   | 54 11.93     | 84 19.27         |                   |
| 6 G C T   | 34 7.44      | 45 10.39         |                   |
| 7 G T C   | 3 0.64       | 55 12.68         |                   |
| 8 G T T   | 7 1.49       | 6 1.43           |                   |

*Calculated by PHASE 2.1 software.

**TABLE 5** Association between the related haplotypes and PDAC risk

| Haplotype | Cases $(n = 228)$ | Controls $(n = 217)$ | Crude OR (95% CI) | $p$ | Adjusted OR$^a$ (95% CI) | $p^a$ |
|-----------|------------------|---------------------|-------------------|------|--------------------------|------|
| a = ACC   |                  |                     |                   |      |                          |      |
| −/−b      | 159 69.74        | 172 80.18           | 1.00              |      | 1.00                     |      |
| a/− + a/a | 69 30.26         | 45 19.82            | 1.66 (1.08–2.56)  | .022 | 1.58 (1.02–2.45)         | .041 |
| b = ACT   |                  |                     |                   |      |                          |      |
| −/−b      | 164 71.93        | 167 79.96           | 1.00              |      | 1.00                     |      |
| b/− + b/b | 64 28.07         | 50 23.04            | 1.30 (0.85–2.00)  | .225 | 1.28 (0.83–1.97)         | .271 |
| c = ATC   |                  |                     |                   |      |                          |      |
| −/−c      | 97 37.28         | 136 62.67           | 1.00              |      | 1.00                     |      |
| c/− + c/c | 131 62.72        | 81 37.33            | 2.27 (1.56–3.32)  |      | 2.16 (1.47–3.18)         | <.001|
| d = ATT   |                  |                     |                   |      |                          |      |
| −/−d      | 189 82.89        | 191 88.02           | 1.00              |      | 1.00                     |      |
| d/− + d/d | 39 17.11         | 26 11.98            | 1.52 (0.89–2.59)  | .128 | 1.42 (0.82–2.44)         | .212 |
| e = GCC   |                  |                     |                   |      |                          |      |
| −/−e      | 184 80.7         | 140 64.52           | 1.00              |      | 1.00                     |      |
| e/− + e/e | 44 19.3          | 77 35.48            | 0.43 (0.28–0.67)  |      | 0.46 (0.30–0.71)         | <.001|
| f = GCT   |                  |                     |                   |      |                          |      |
| −/−f      | 199 87.28        | 178 82.03           | 1.00              |      | 1.00                     |      |
| f/− + f/f | 29 12.72         | 39 17.97            | 0.67 (0.39–1.12)  | .125 | 0.66 (0.39–1.11)         | .119 |
| g = GTC   |                  |                     |                   |      |                          |      |
| −/−g      | 225 98.68        | 168 77.42           | 1.00              |      | 1.00                     |      |
| g/− + g/g | 3 1.32           | 49 22.58            | 0.05 (0.01–0.15)  |      | 0.04 (0.01–0.14)         | <.001|
| h = GTT   |                  |                     |                   |      |                          |      |
| −/−h      | 221 96.93        | 211 97.24           | 1.00              |      | 1.00                     |      |
| h/− + h/h | 7 3.07           | 6 2.76              | 1.11 (0.37–3.37)  | .849 | 1.01 (0.33–3.11)         | .99  |

*Bold values in this table indicate the significant differences ($P < .05$).

$^a$Unconditional logistic regression adjusted for risk factors (age, gender, tobacco smoking, alcohol consumption, diabetes, and family history of cancer).

$^b$Indicates any haplotype, for example: a/− denotes the haplotype a = ACC combined with any other haplotypes.
susceptibility to PDAC, to the best of our knowledge. In the present study, the frequencies of genotypes AG and GG, as well as allele G in ABCB1 rs4148737 were significantly lower in patients with PDAC compared with the controls. Therefore, these variant genotypes and alleles may decrease an individual susceptibility to PDAC. This interpretation of the result agrees with ABCB1’s possible protective functions and is similar to previous studies on outcomes of treatments in patients with Ewing sarcoma (Ruiz-Pinto et al., 2016) and osteosarcoma survival following chemotherapy (He et al., 2013). Stratification by sex, age, smoking status, drinking status, diabetes, and family history of cancer showed that individuals with genotypes AG and GG still exhibited a reduced risk of developing PDAC, highlighting the protective role of these SNPs.

Additionally, although NAMPT rs2505568 and rs9034 are located in the 3’ untranslated region, which may affect NAMPT expression, their polymorphisms were found to be independent of the development of dilated cardiomyopathy, esophageal squamous cell carcinoma (ESCC), and bladder cancer (Dou et al., 2015; Zhang et al., 2015; Zhang, Zhou, et al., 2014). APOB rs1997623 and rs12672038 were reported to have no influence on ESCC or gastric cancer (Rawla et al., 2019; Zhang, Hu, et al., 2014). As these four SNPs are not associated with PDAC, these results are consistent with previous studies.

The other SNPs tested in the present study were determined to not be significantly associated with the development of PDAC, which differs from previous studies in different types of cancer. A silent mutation at ABCB1 rs1045642 may decrease the expression levels of the mRNA and protein products, or alter the protein structure and substrate affinity (Cascorbi, 2006; Kimchi-Sarfaty et al., 2007). Genotype TT was found to significantly increase the overall risk of gastric cancer in Iranian individuals (Sabahi et al., 2010; Sam et al., 2007), and was associated with colorectal cancer and multiple myeloma in French individuals (Falkowski et al., 2017; Razi, Anani Sarab, Omidkhoda, & Alizadeh, 2018). There is a correlation between SNPs at rs3789243 with colorectal cancer (Andersen et al., 2013). Furthermore, SNPs at APOB rs693 resulting in amino acid substitution and SNPs at rs104203, which result in a silent mutation, have been reported to be associated with dyslipidemia (Tsunoda, Harihara, Tanabe, & Dashnayam, 2012) and an increased risk of breast cancer in Chinese individuals (Liu et al., 2013). CA9 rs3807987 and rs7804372 are located in introns, but intron polymorphisms may influence CA9 expression levels and protein function by compounding with nearby polymorphisms, alternative splicing, and affecting the stability of mRNA during the progression of the cancer. These two SNPs are associated with susceptibility to ESCC, breast, and gastric cancer (Wang et al., 2014; Yan et al., 2019; Zhang, Hu, et al., 2014). NAMPT rs61330082 in the promoter region may influence NAMPT structure, function, or expression, which is similar to its role in increasing the risk of ESCC and bladder cancer (Zhang et al., 2015; Zhang, Zhou, et al., 2014).

The varying results of the seven SNPs and their effects on tumorigenesis between the present and previous studies may primarily be due to different tumor locations, tumor pathological status, tumor differentiation status, demographics, and limited number of samples available.

To analyze the combined effects of multiple loci, haplotype analyses were used to assess genetic susceptibility with increased accuracy. Based on the genotypes at ABCB1 rs4148737A, rs1045642, and rs3789243, the presence of haplotypes ACC and ATC was constructed and positively correlated with the development of PDAC, whereas haplotypes GCC and GTC protected carriers from PDAC. Thus, the impact of allele G or A at rs4148737 among the three SNPs was thus determined to be important, which is consistent with the positive effect of allele A on PDAC tumorigenesis.

Due to a lower incidence, atypical clinical manifestations, insensitive early diagnostic tools, rapid development of the cancer, and limited treatment regimens for patients with advanced-staged cancer, the number of PDAC cases is significantly lower compared with other types of cancer of the digestive system, particularly cases with identified pathological results. The strengths of the present study include the relatively large sample size from the same geographical area. However, the present study has some limitations. Sample size determination was not based on power calculations, which may affect the accuracy of the results to a certain extent, particularly as the sample sizes were smaller when the patients were stratified. These results need to be further confirmed using a larger sample from patients in regions with a higher incidence of PDAC, and from different ethnicities. Additionally, if the study participants were relatively homogeneous in terms of general characteristics, genetic backgrounds, and environmental risk factors, the results would be more accurate. Gene–environment interaction studies and functional studies are required to confirm these results and determine the effects of ABCB1 genetic polymorphisms on PDAC.

In summary, the present study showed that genetic polymorphism of ABCB1 rs4148737 was significantly associated with PDAC susceptibility in Chinese patients. Genotypes AG and GG, allele G, as well as haplotypes GCC and GTC may be protective predictive factors for PDAC. Therefore, SNPs at rs4148737 may serve as an efficient genetic susceptibility marker, and possibly a potential target for development of tools for early diagnosis, genetic prediction, and individualized genetic therapy in the future.
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
The present study was approved by the Ethics Committee of Shandong Provincial Qianfoshan Hospital and written informed consent was obtained from all participants.

COMPETING INTERESTS
The authors declare that they have no competing interests.

ACKNOWLEDGMENT
We are grateful to the patients and control individuals involved in this study for providing their general information and blood samples.

AUTHOR CONTRIBUTION
Zhang, C. devised and supervised the project, and drafted the manuscript. Li, B. and Wang, J. were involved in carrying out the experiment. Zhang, M. performed the experimental data and statistical analysis. Liu, C. and Chen, Z. aided in interpreting the results and worked the manuscript.

ORCID
Chuazhen Zhang https://orcid.org/0000-0002-6408-7390

REFERENCES
Al-Bustan, S. A., Alnaqeeb, M. A., Annice, B. G., Ebrahim, G. A., & Refai, T. M. (2014). Genetic association of APOB polymorphisms with variation in serum lipid profile among the Kuwait population. *Lipids in Health and Disease*, 13, 157. https://doi.org/10.1186/1476-511X-13-157

Andersen, V., Vogel, U., Godiksen, S., Frenzel, F. B., Siebø, M., Hamfjord, J., … Vogel, L. K. (2013). Low ABCB1 gene expression is an early event in colorectal carcinogenesis. *PLoS ONE*, 8(8), e72119. https://doi.org/10.1371/journal.pone.0072119

Berrington de Gonzalez, A., Sweetland, S., & Spencer, E. (2003). A meta-analysis of obesity and the risk of pancreatic cancer. *British Journal of Cancer*, 89(3), 519–523. https://doi.org/10.1038/sj.bjc.6601140

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6), 394–424. https://doi.org/10.3322/caac.21492

Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *The New England Journal of Medicine*, 348(17), 1625–1638. https://doi.org/10.1056/NEJMoa021423

Caronia, D., Patiño-Garcia, A., Pérez-Martínez, A., Pita, G., Moreno, L. T., Zalacain-Díez, M., … Gonzalez-Neira, A. (2011). Effect of ABCB1 and ABCB3 polymorphisms on osteosarcoma survivor after chemotherapy: A pharmacogenetic study. *PLoS ONE*, 6(10), e26091. https://doi.org/10.1371/journal.pone.0026091

Cascoiri, I. (2006). Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. *Pharmacology & Therapeutics*, 112(2), 457–473. https://doi.org/10.1016/j.pharmthera.2006.04.009

Couet, J., Sargiacomo, M., & Lisanti, M. P. (1997). Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. *The Journal of Biological Chemistry*, 272(48), 30429–30438. https://doi.org/10.1074/jbc.272.48.30429

Davoodi, S. H., Malek-Shahabi, T., Malekshahi-Moghadam, A., Shahbazi, R., & Esmaeili, S. (2013). Obesity as an important risk factor for certain types of cancer. *Iranian Journal of Cancer Prevention*, 6(4), 186–194.

De La Cruz, M. S., Young, A. P., & Ruffin, M. T. (2014). Diagnosis and management of pancreatic cancer. *American Family Physician*, 89(8), 626–632.

Dou, Q., Peng, Y., Zhou, B., Zhang, K., Lin, J., Dai, X., … Rao, L. I. (2015). Association of Nicotinamide Phosphoribosyltransferase (NAMPT) gene polymorphisms and of serum NAMPT levels with dilated cardiomyopathy in a Chinese population. *International Journal of Molecular Sciences*, 16(9), 22299–22318. https://doi.org/10.3390/ijms16092299

Falkowskii, S., Woillard, J.-B., Postil, D., Tubiana-Mathieu, N., Terrebonne, E., Pariente, A., … Picard, N. (2017). Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: A case control study. *BMJ Cancer*, 17(1), 901. https://doi.org/10.1186/s12885-017-3728-0

Fung, K. L., & Gottesman, M. M. (2009). A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. *Biochimica Et Biophysica Acta*, 1794(5), 860–871. https://doi.org/10.1016/j.bbapap.2009.02.014

Ghirozzi, P. (2014). Genetic predisposition to pancreatic cancer. *World Journal of Gastroenterology*, 20(31), 10778–10789. https://doi.org/10.3748/wjg.v20.i31.10778

Guillaumond, F., Bidaut, G., Ouaissi, M., Servais, S.,bourand, O., Olivares, O., … Vasseur, S. (2015). Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. *Proceedings of the National Academy of Sciences, USA*, 112(8), 2473–2478. https://doi.org/10.1073/pnas.1421601112

Gupta, R., Toufaily, C., & Annabi, B. (2014). Caveolin and cavin family members: dual roles in cancer. *Biochimie*, 107, 188–202. https://doi.org/10.1016/j.bioch.2014.09.010.

Hackeng, W. M., Hruban, R. H., Offerhaus, G. J., & Brossen, L. A. (2016). Surgical and molecular pathology of pancreatic neoplasms. *Diagnostic Pathology*, 11(1), 47. https://doi.org/10.1016/s1300-016-0497-z

Hartmann, G., Kim, H., & Piquette-Miller, M. (2001). Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. *International Immunopharmacology*, 1(2), 189–199. https://doi.org/10.1016/ s0162-3109(00)00271-x

He, T., Mo, A., Zhang, K., & Liu, L. (2013). ABCB1/MDR1 gene polymorphism and colorectal cancer risk: A meta-analysis of case-control studies. *Colorectal Disease: The Official Journal of Coloproctology of Great Britain and Ireland*, 15(1), 12–18. https://doi.org/10.1111/j.1463-1318.2012.02919.x

Hodges, L. M., Markova, S. M., Chinn, L. W., Gow, J. M., Kroetz, D. L., Klein, T. E., & Altman, R. B. (2011). Very important pharmacogenomic summary: ABCB1 (MDR1, P-glycoprotein). *Pharmacogenetics & Genomics*, 21(3), 152–161. https://doi.org/10.1097/FPC.0b013e3283385a1c

Hsu, C. M., Yang, M. D., Tsai, C. W., Ho, C. Y., Chang, W. S., Chang, S. C., … Bau, D. T. (2013). The contribution of caveolin-1 genotype
and phenotype to hepatocellular carcinoma. *Anticancer Research*, 33(2), 671–677.

Ju, H., Zou, R., Venema, V. J., & Venema, R. C. (1997). Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. *The Journal of Biological Chemistry*, 272(30), 18522–18525. https://doi.org/10.1074/jbc.272.30.18522

Kasuya, K., Tsuchida, A., Suzuki, M., Nagakawa, Y., Tanaka, H., Ota, H., ... Aoki, T. (2012). Single nucleotide polymorphism of multidrug-resistance 1 and anti-multidrug-resistance 1 single chain antibody treatment for the pancreatic cancer cell line. *Hepato-gastroenterology*, 59(113), 272–275. https://doi.org/10.5754/hge11377

Kim, S.-R., Bae, S.-K., Choi, K.-S., Park, S.-Y., Jun, H. O., Lee, J.-Y., ... Bae, M.-K. (2007). Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. *Biochemical and Biophysical Research Communications*, 357(1), 150–156. https://doi.org/10.1016/j.bbrc.2007.03.105

Kimchi-Sarfaty, C., Oh, J. M., Kim, I. W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007). A “silent” polymorphism in the MDRI gene changes substrate specificity. *Science (New York, N.Y.)*, 315(5811), 525–528. https://doi.org/10.1126/science.1135308

Liu, X., Wang, Y., Qu, H., Hou, M., Cao, W., Ma, Z., & Wang, H. (2013). Associations of polymorphisms of rs693 and rs1042031 in apolipoprotein B gene with risk of breast cancer in Chinese. *Japanese Journal of Clinical Oncology*, 43(4), 362–368. https://doi.org/10.1093/jjco/hyt018

Longnecker, D. S., Karagas, M. R., Tosteson, T. D., & Mott, L. A. (2000). Racial differences in pancreatic cancer: Comparison of survival and histologic types of pancreatic carcinoma in Asians, blacks, and whites in the United States. *Pancreas*, 21(4), 338–343. https://doi.org/10.1097/00002667-200011000-00003

Midha, S., Chawla, S., & Garg, P. K. (2016). Modifiable and non-modifiable risk factors for pancreatic cancer: A review. *Cancer Letters*, 381(1), 269–277. https://doi.org/10.1016/j.canlet.2016.07.022

Mohammed, S., Van Buren 2nd, G., & Fisher, W. E. (2014). Pancreatic cancer: Advances in treatment. *World Journal of Gastroenterology*, 20(28), 9354–9360. https://doi.org/10.3748/wjg.v20.i28.9354

Rawla, P., Sunkara, T., & Gaduputi, V. (2019). Epidemiology of pancreatic cancer: global trends, etiology and risk factors. *World Journal of Oncology*, 10(1), 10–27. https://doi.org/10.14740/wjon1166

Razi, B., Anani Sarab, G., Omidkhoda, A., & Alizadeh, S. (2018). Multidrug resistance 1 (MDR1/ABCB1) gene polymorphism (rs1045642 C > T) and susceptibility to multiple myeloma: A systematic review and meta-analysis. *Hematology (Amsterdam, Netherlands)*, 23(8), 456–462. https://doi.org/10.1080/1024332.2018.1443897

Ruiz-Pinto, S., Pita, G., Patiño-García, A., García-Miguel, P., Alonso, J., Pérez-Martínez, A., ... González-Neira, A. (2016). Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, 27(9), 1788–1793. https://doi.org/10.1093/annonc/mdw234

Sabahi, S., Salek, R., Heravi, R. E., Mosaffa, F., Avanaki, Z. J., & Behravan, J. (2010). Association of gastric cancer incidence with MDR1 gene polymorphism in an ethnic Iranian population. *Indian Journal of Cancer*, 47(3), 317–321. https://doi.org/10.4103/0019-509X.64723

Sam, S. S., Thomas, V., Sivagnanam, K., Reddy, K. S., Surianarayanan, G., & Chandrasekaran, A. (2007). ABCB1 genetic polymorphism and risk of upper aerodigestive tract cancers among smokers, tobacco chewers and alcoholics in an Indian population. *Pharmacogenetics and Genomics*, 17(10), 861–866. https://doi.org/10.1097/FPC.0b013e3282c4bf18a

Sarnecka, A. K., Zagozda, M., & Durlik, M. (2016). An overview of genetic changes and risk of pancreatic ductal adenocarcinoma. *Journal of Cancer*, 7(14), 2045–2051. https://doi.org/10.7150/jca.15323

Shackelford, R. E., Mayhall, K., Maxwell, N. M., Kandil, E., & Coppola, D. (2013). Nicotinamide phosphoribosyltransferase in malignancy: A review. *Genes & Cancer*, 4(11–12), 447–456. https://doi.org/10.1089/gcc.2013.07576

Shatz, M., & Liscovitch, M. (2008). Caveolin-1: A tumor-promoting role in human cancer. *International Journal of Radiation Biology*, 84(3), 177–189. https://doi.org/10.1080/09553000701745293

Shi, C., Daniels, J. A., & Hruban, R. H. (2008). Molecular characterization of pancreatic neoplasms. *Advances in Anatomic Pathology*, 15(4), 185–195. https://doi.org/10.1097/PAP.0b013e3181bf57d

Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. *CA: A Cancer Journal for Clinicians*, 68(1), 7–30. https://doi.org/10.3322/caac.21442

Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. *CA: A Cancer Journal for Clinicians*, 69(1), 7–34. https://doi.org/10.3322/caac.21551

Solomon, S., Das, S., Brand, R., & Whitcomb, D. C. (2012). Inherited pancreatic cancer syndromes. *Cancer Journal (Sudbury, Mass.)*, 18(6), 485–491. https://doi.org/10.1002/cncr.215510

Tanaka, M., Okazaki, T., Suzuki, H., Abbruzzese, J. L., & Li, D. (2011). Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. *Cancer*, 117(4), 744–751. https://doi.org/10.1002/cncr.25510

Tsunoda, K., Harihara, S., Tanabe, Y., & Dashnaym, B. (2012). Polymorphism of the apolipoprotein B gene and association with plasma lipid and lipoprotein levels in the Mongolian Buryat. *Biochemical Genetics*, 50(3–4), 249–268. https://doi.org/10.1007/s10528-011-9468-y

Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011). Pancreatic cancer. *Lancet (London, England)*, 378(9791), 607–620. https://doi.org/10.1016/S0140-6736(10)62307-0

Wang, S., Zhang, C., Liu, Y., Xu, C., & Chen, Z. (2014). Functional polymorphisms of caveolin-1 variants as potential biomarkers of esophageal squamous cell carcinoma. *Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals*, 19(8), 652–659. https://doi.org/10.3109/1354755X.2014.968210

Yan, C., Sun, C., Ding, X., Rizeq, F. K., Ren, M., Yang, F., ... Wang, B. (2019). Association of CAV1 polymorphisms with the risks of breast cancer: A systematic review and meta-analysis. *Pathology, Research and Practice*, 215(9), 152518. https://doi.org/10.1016/j.prp.2019.152518

Yang, M. D., Tsai, R. Y., Liu, C. S., Chang, C. H., Wang, H. C., Tsou, Y. A., ... Bau, D. T. (2010). Association of Caveolin-1 polymorphisms with colorectal cancer susceptibility in Taiwan. *World Journal of Gastrointestinal Oncology*, 2(8), 326–331. https://doi.org/10.4251/wjgo.v2i8.326

Yang, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016). Genetics and biology of pancreatic ductal adenocarcinoma. *Genes & Development*, 30(4), 355–385. https://doi.org/10.1101/gad.275776.115
Ying, W. (2008). NAD+/NADH and NADP+/NADPH in cellular functions and cell death: Regulation and biological consequences. *Antioxidants & Redox Signaling, 10*(2), 179–206. https://doi.org/10.1089/ars.2007.1672

Zhang, C., Yan, D., Wang, S., Xu, C., Du, W., Ning, T., … Chen, Z. (2015). Genetic polymorphisms of NAMPT related with susceptibility to esophageal squamous cell carcinoma. *BMC Gastroenterology, 15*, 49. https://doi.org/10.1186/s12877-015-0282-6

Zhang, K., Zhou, B., Zhang, P., Zhang, Z., Chen, P., Pu, Y., … Zhang, L. (2014). Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group. *Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 35*(5), 4031–4040. https://doi.org/10.1007/s13277-013-1527-z

Zhang, Y., Hu, X. J., Zhang, L. L., Sun, L. P., Yuan, Y., Qu, X. J., & Liu, Y. P. (2014). Interaction among Caveolin-1 genotypes (rs3807987/rs7804372), *H. pylori* infection, and risk of gastric cancer in a Chinese population. *Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine, 35*(2), 1511–1516. https://doi.org/10.1007/s13277-013-1208-y

Zheng, R. S., Sun, K. X., Zhang, S. W., Zeng, H. M., Zou, X. N., Chen, R., … He, J. (2019). Report of cancer epidemiology in China, 2015. *Zhonghua Zhong Liu Za Zhi. [Chinese Journal of Oncology], 41*(1), 19–28. https://doi.org/10.3760/cma.j.issn.0253-3766.2019.01.005

How to cite this article: Li B, Zhang C, Wang J, Zhang M, Liu C, Chen Z. Impact of genetic variants of *ABCB1, APOB, CAV1,* and NAMPT on susceptibility to pancreatic ductal adenocarcinoma in Chinese patients. *Mol Genet Genomic Med.* 2020;8:e1226. https://doi.org/10.1002/mgg3.1226